Ceftriaxone
Ceftriaxone, Rocephin (ceftriaxone) is a small molecule pharmaceutical. Ceftriaxone was first approved as Rocephin on 1984-12-21. It is used to treat acinetobacter infections, bacterial infections, bacterial meningitis, bacterial pneumonia, and bacterial skin diseases amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ceftriaxone sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER | B. Braun Medical | N-050796 RX | 2005-04-20 | 2 products, RLD, RS |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ceftriaxone | ANDA | 2024-02-06 |
| ceftriaxone and dextrose | New Drug Application | 2022-01-13 |
| ceftriaxone ceftriaxone | ANDA | 2019-08-14 |
| ceftriaxone sodium | ANDA | 2024-02-13 |
| easy-ceft | ANDA | 2021-01-07 |
Indications
FDA
EMA
Show 18 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0696 | Injection, ceftriaxone sodium, per 250 mg |
Clinical
Clinical Trials
236 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pneumonia | D011014 | EFO_0003106 | — | 1 | 5 | 12 | 4 | 5 | 23 |
| Gonorrhea | D006069 | DOID_7551 | A54 | — | 3 | 4 | 2 | 3 | 12 |
| Infections | D007239 | EFO_0000544 | — | 1 | 1 | 4 | 4 | 2 | 11 |
| Sepsis | D018805 | HP_0100806 | A41.9 | — | 1 | 5 | 3 | 2 | 10 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | 1 | 1 | 4 | 2 | 1 | 9 |
| Appendicitis | D001064 | EFO_0007149 | K37 | — | 1 | — | 4 | 4 | 9 |
| Intraabdominal infections | D059413 | — | — | — | — | 5 | 2 | — | 7 |
| Critical illness | D016638 | — | — | — | — | 1 | 1 | 4 | 6 |
| Lyme disease | D008193 | — | A69.2 | — | 1 | 2 | 1 | 1 | 5 |
| Septic shock | D012772 | — | A48.3 | — | — | 2 | 2 | 1 | 5 |
Show 37 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | 3 | 7 | — | — | 10 |
| Covid-19 | D000086382 | — | U07.1 | 1 | 2 | 1 | — | 1 | 5 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | 2 | — | 3 | 5 |
| Bacterial infections | D001424 | — | A49 | — | — | 1 | — | 3 | 4 |
| Pharmacokinetics | D010599 | — | — | — | 1 | 1 | — | 2 | 3 |
| Microbial drug resistance | D004352 | — | — | — | — | 1 | — | 1 | 2 |
| Community-acquired infections | D017714 | — | — | — | 1 | 2 | — | — | 2 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | 1 | 2 | — | — | 2 |
| Amyotrophic lateral sclerosis | D000690 | HP_0007354 | G12.21 | — | — | 1 | — | 1 | 2 |
| Antibiotic prophylaxis | D019072 | — | — | — | 1 | 1 | — | — | 2 |
Show 8 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | 2 | — | — | — | 4 |
| Chlamydia infections | D002690 | EFO_0007205 | A74.9 | — | 1 | — | — | 2 | 3 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 1 | — | — | 1 | 2 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 1 | — | — | 1 | 2 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 1 | — | — | — | 1 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | 1 | — | — | — | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | — | — | — | 1 |
| Endometritis | D004716 | EFO_1001312 | — | — | 1 | — | — | — | 1 |
| Pelvic inflammatory disease | D000292 | EFO_1001388 | N70-N77 | — | 1 | — | — | — | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 1 | — | — | — | 1 |
Show 11 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | 1 | — | — | — | 1 | 2 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | 1 | 2 |
| Male genital diseases | D005832 | EFO_0009555 | N50.9 | 1 | — | — | — | — | 1 |
| Male urogenital diseases | D052801 | — | — | 1 | — | — | — | — | 1 |
| Prostatic diseases | D011469 | — | N42.9 | 1 | — | — | — | — | 1 |
| Colonic neoplasms | D003110 | — | C18 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | — | 2 | 2 |
| Ultrasonography | D014463 | — | — | — | — | — | — | 1 | 1 |
| Inappropriate prescribing | D057970 | — | — | — | — | — | — | 1 | 1 |
| Escherichia coli infections | D004927 | EFO_1001318 | B96.20 | — | — | — | — | 1 | 1 |
| Laparotomy | D007813 | — | — | — | — | — | — | 1 | 1 |
| Tick-borne encephalitis | D004675 | EFO_1001309 | A84 | — | — | — | — | 1 | 1 |
| Granulomatous mastitis | D058890 | — | N61.2 | — | — | — | — | 1 | 1 |
| Subcutaneous injections | D007279 | — | — | — | — | — | — | 1 | 1 |
| Pregnancy rate | D018873 | — | — | — | — | — | — | 1 | 1 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | — | — | — | 1 | 1 |
Show 12 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ceftriaxone |
| INN | ceftriaxone |
| Description | Ceftriaxone is a third-generation cephalosporin compound having 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetylamino and [(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl side-groups. It has a role as an antibacterial drug, an EC 3.5.2.6 (beta-lactamase) inhibitor and a drug allergen. It is a cephalosporin, a member of 1,2,4-triazines, a member of 1,3-thiazoles and an oxime O-ether. It is a conjugate acid of a ceftriaxone(1-). |
| Classification | Small molecule |
| Drug class | cephalosporins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1 |
Identifiers
| PDB | — |
| CAS-ID | 73384-59-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL161 |
| ChEBI ID | 29007 |
| PubChem CID | 5479530 |
| DrugBank | DB01212 |
| UNII ID | 75J73V1629 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Rocephin – Roche
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Ceftriaxone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 54,479 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
21,069 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use